Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Carcinoma, Neuroendocrine × Methods × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 25 Neoplasms 23 Uterine Cervical Neoplasms 10 Lung Neoplasms 10 Colorectal Neoplasms 8 Colonic Neoplasms 8 Motor Activity 7 Urinary Bladder Neoplasms 6 Rectal Neoplasms 6 Vulvar Neoplasms 5 Obesity 5 Endometrial Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Melanoma 4 Head and Neck Neoplasms 4 Anxiety Disorders 4 Stomach Neoplasms 3 Sarcoma 3 Hematopoietic and Lymphoid System Neoplasm 3 Depression 3 Carcinoma, Ovarian Epithelial 3 Breast Carcinoma In Situ 3 Vaginal Neoplasms 2 Testicular Neoplasms 2 Skin Neoplasms 2 Psychological Well-Being 2 Prostatic Neoplasms 2 Papillomavirus Infections 2 Pancreatic Neoplasms 2 Pain 2

Interventions

Everolimus 7 avelumab 3 Etoposide 3 Cisplatin 3 Bevacizumab 3 azaspirane 2 Temozolomide 2 Irinotecan 2 veliparib 1 tocilizumab 1 selinexor 1 pralsetinib 1 pertuzumab 1 pembrolizumab 1 pasireotide 1 irinotecan sucrosofate 1 gallium Ga 68 dotatate 1 carfilzomib 1 berzosertib 1 belinostat 1 Topotecan 1 TLC 388 1 Radiotherapy 1 Radiosurgery 1 Positron Emission Tomography Computed Tomography 1 Podophyllotoxin 1 Platinum 1 Paclitaxel 1 Octreotide 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04478175 2022-11-17

DParcoursDig

Institut Curie

Phase NA Completed

Neoplasms, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡